Examination of tissue protection and regeneration effect of heparin affinity erythropoietin

Research Project

Project/Area Number	16K09823
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Hematology
Research Institution	Niigata University
Principal Investigator	MORIYAMA MASATO 新潟大学, 医歯学系, 准教授 (30598131)
Co-Investigator(Kenkyū-buntansha)	西條康夫新潟大学, 医歯学系, 教授 (10270828) 小澤拓也新潟大学, 医歯学系, 講師 (70467075)
Project Period (FY)	2016-04-01 – 2019-03-31
Project Status	Completed (Fiscal Year 2018)
Budget Amount *help	¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000) Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	エリスロポエチン / ヘパリン親和性 / ヘパリン結合ドメイン / 血栓 / 組織保護 / 血管障害 / 細胞外マトリックス / サイトカイン
Outline of Final Research Achievements	Erythropoietin (EPO) has been used as an erythropoietic stimulant, and it is also shows tissue-protective and regenerative effects. We synthesized a hybrid molecule of EPO ; heparin affinity erythropoietin (HEPO), and studied the biological characteristics of this novel EPO derivative. Human HEPO (rhHEPO) shows not only long-acting erythropoietic activity, but also antiangiogenic effect. This novel EPO derivative (HEPO) may have advantages to act on thrombosis and hemostasis, in addition to tissue-protective and anti-tumor effects.
Academic Significance and Societal Importance of the Research Achievements	HEPOは赤血球造血作用を保ちつつ、ヘパリン親和性が付与されたことにより、長時間造血作用を示すとともに、抗腫瘍性も獲得している。rhHEPOは特許化されており、近年ではがんと血栓塞栓症の関連性が注目されていることから、その機序や治療を研究する上で重要であると考える。